Literature DB >> 11413529

Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study.

B C Song1, Y H Chung, J A Kim, H C Lee, H K Yoon, K B Sung, S H Yang, K Yoo, Y S Lee, D J Suh.   

Abstract

BACKGROUND: Hypoxia up-regulates insulin-like growth factor-2 (IGF-2) and thus stimulates the growth of hepatocellular carcinoma (HCC) cells. In the current study, the authors prospectively evaluated changes in plasma IGF-2 levels in HCC patients after transcatheter arterial chemoembolization (TACE), which usually results in hypoxic insult to liver tissue. The authors also examined the association between changes in plasma IGF-2 levels after TACE and HCC progression, especially in relation to metastasis.
METHODS: Plasma IGF-2 levels were measured before and 4 weeks after TACE in 46 patients with HCC. Three months after TACE, the patients were evaluated for the occurrence of metastatic HCC.
RESULTS: In 13 of the 46 patients, post-TACE plasma IGF-2 levels decreased by > 20% (Group 1) compared with their basal levels; in 18 patients, the IGF-2 levels changed within 20% (Group 2) and in 15 patients the IGF-2 levels increased by > 20% (Group 3). Plasma IGF-2 levels had a tendency to increase in patients with large-sized tumors, high serum alpha-fetoprotein (AFP) levels, and the heterogeneous uptake of iodized oil. Metastatic foci were found in 9 patients in Group 3 (60%), in contrast to only 3 patients in Group 2 (17%) and in none of the patients in Group 1 (P = 0.001). On multivariate analysis, higher Child-Pugh scores and increased plasma IGF-2 levels (Group 3) were found to be independent risk factors for metastasis.
CONCLUSIONS: Increased plasma IGF-2 levels after TACE, which are common in patients with large-sized tumors and high serum AFP levels, appear to be associated with the occurrence of metastatic HCC after TACE. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413529

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

2.  Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.

Authors:  Martin-Walter Welker; Stephan Zangos; Susanne Kriener; Christian Mönch; Stefan Zeuzem; Joerg Trojan
Journal:  J Gastrointest Cancer       Date:  2010-06

3.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

4.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 5.  Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.

Authors:  Girolamo Ranieri; Ilaria Marech; Vito Lorusso; Veronica Goffredo; Angelo Paradiso; Domenico Ribatti; Cosmo Damiano Gadaleta
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

6.  Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization.

Authors:  Xiao-Feng Liao; Ji-Lin Yi; Xing-Rui Li; Wei Deng; Zhi-Fang Yang; Geng Tian
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

7.  Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Xiaofeng Liao; Jilin Yi; Xingrui Li; Zhifang Yang; Wei Deng; Geng Tian
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

8.  Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?

Authors:  Andrew C Cupino; Clark D Hair; John F Angle; Stephen H Caldwell; Tyvin A Rich; Carl L Berg; Patrick G Northup; Abdullah M S Al-Osaimi; Curtis K Argo
Journal:  Gastrointest Cancer Res       Date:  2012-01

9.  Expression of hypoxia-inducible factor-1alpha in liver tumors after transcatheter arterial embolization in an animal model.

Authors:  Bin Liang; Chuansheng Zheng; Gansheng Feng; Yong Wang; Hui Zhao; Huimin Liang; Enhua Xiao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

10.  Selection of Mesenchymal-Like Metastatic Cells in Primary Tumors - An in silico Investigation.

Authors:  Vipin Narang; Shek Yoon Wong; Shiang Rong Leong; Bindu Harish; Jean-Pierre Abastado; Alexandre Gouaillard
Journal:  Front Immunol       Date:  2012-04-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.